Eclipse Bioinnovations Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
44
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$4.91M
- Investors
-
11
Eclipse Bioinnovations General Information
Description
Developer of cell-free genomics technologies designed to provide specialized genomics-based products and services. The company's technology focuses on increasing crosslinking and immunoprecipitation and assists in identifying ribonucleic acid binding protein targets, enabling scientists and academic customers to accelerate research and develop new and effective drugs to cure a wide range of human diseases.
Contact Information
Website
eclipsebio.comCorporate Office
- 5770 Oberlin Drive
- San Diego, CA 92121
- United States
Corporate Office
- 5770 Oberlin Drive
- San Diego, CA 92121
- United States
Eclipse Bioinnovations Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series A) | 01-Jan-2026 | $4.91M | Completed | Generating Revenue | ||
| 7. Grant | 22-Sep-2021 | Completed | Generating Revenue | |||
| 6. Early Stage VC (Series A) | 10-Sep-2021 | Completed | Generating Revenue | |||
| 5. Seed Round | 05-Jun-2020 | Completed | Generating Revenue | |||
| 4. Debt - PPP | 03-May-2020 | Completed | Generating Revenue | |||
| 3. Grant | 17-Sep-2019 | Completed | Startup | |||
| 2. Grant | 01-Jan-2019 | $1.93M | Completed | Startup | ||
| 1. University Spin-Out | 01-Jan-2017 | Completed | Startup |
Eclipse Bioinnovations Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 | ||||||||
| Series A-1 | ||||||||
| Series A | ||||||||
| Seed 2 | 176,825 | $0.000100 | $11.31 | $11.31 | 1x | $11.31 | 4.72% | |
| Seed | 333,413 | $0.000100 | $7.5 | $7.5 | 1x | $7.5 | 8.9% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Eclipse Bioinnovations Comparisons
Industry
Financing
Details
Eclipse Bioinnovations Competitors (13)
One of Eclipse Bioinnovations’s 13 competitors is LC Sciences, a Corporation company based in Houston, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| LC Sciences | Corporation | Houston, TX | ||||
| Paragon Genomics | Venture Capital-Backed | Fremont, CA | ||||
| Novogene | Formerly PE-Backed | Beijing, China | ||||
| Oxford Nanopore Technologies | Formerly VC-backed | Oxford, United Kingdom | ||||
| Ambry Genetics | Formerly PE-Backed | Aliso Viejo, CA |
Eclipse Bioinnovations Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Eclipse Bioinnovations Patents
Eclipse Bioinnovations Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260250666-A1 | Methods for obtaining rna secondary structure of lnp-encapsulated rna | Pending | 03-Jun-2022 | ||
| WO-2023235820-A1 | Methods for obtaining rna secondary structure of lnp-encapsulated rna | Inactive | 03-Jun-2022 | ||
| EP-4482954-A2 | Methods for oligo targeted proximity ligation | Pending | 25-Feb-2022 | ||
| EP-4482954-A4 | Methods for oligo targeted proximity ligation | Pending | 25-Feb-2022 | ||
| US-20230313177-A1 | Methods for oligo targeted proximity ligation | Pending | 25-Feb-2022 | C12N15/1065 |
Eclipse Bioinnovations Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Eclipse Bioinnovations Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Brainstorm Ventures | Venture Capital | Minority | ||
| Economic Development Innovations Singapore | PE/Buyout | Minority | ||
| Magnetic Ventures | Venture Capital | Minority | ||
| U.S. Department of Health and Human Services | Government | |||
| Alexandria Venture Investments | Venture Capital | Minority |
Eclipse Bioinnovations Acquisitions (1)
Eclipse Bioinnovations’s most recent deal was a Merger/Acquisition with Terrain Bio. The deal was made on 26-Jan-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Terrain Bio | 26-Jan-2026 | Merger/Acquisition | Biotechnology |
Eclipse Bioinnovations FAQs
-
When was Eclipse Bioinnovations founded?
Eclipse Bioinnovations was founded in 2017.
-
Where is Eclipse Bioinnovations headquartered?
Eclipse Bioinnovations is headquartered in San Diego, CA.
-
What is the size of Eclipse Bioinnovations?
Eclipse Bioinnovations has 44 total employees.
-
What industry is Eclipse Bioinnovations in?
Eclipse Bioinnovations’s primary industry is Drug Discovery.
-
Is Eclipse Bioinnovations a private or public company?
Eclipse Bioinnovations is a Private company.
-
What is the current valuation of Eclipse Bioinnovations?
The current valuation of Eclipse Bioinnovations is .
-
What is Eclipse Bioinnovations’s current revenue?
The current revenue for Eclipse Bioinnovations is .
-
How much funding has Eclipse Bioinnovations raised over time?
Eclipse Bioinnovations has raised $23.9M.
-
Who are Eclipse Bioinnovations’s investors?
Brainstorm Ventures, Economic Development Innovations Singapore, Magnetic Ventures, U.S. Department of Health and Human Services, and Alexandria Venture Investments are 5 of 11 investors who have invested in Eclipse Bioinnovations.
-
Who are Eclipse Bioinnovations’s competitors?
LC Sciences, Paragon Genomics, Novogene, Oxford Nanopore Technologies, and Ambry Genetics are some of the 13 competitors of Eclipse Bioinnovations.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
